Literature DB >> 7141570

Transnitrosation by nitrosamines in vivo.

W Lijinsky, M D Reuber.   

Abstract

The significance of in vivo transnitrosation in carcinogenesis by the nitrosamines formed was studied by feeding mixtures of morpholine and nitrosamines to rats for most of their lifespan. In some groups, a transnitrosation catalyst (sodium thiocyanate) was fed simultaneously. None of the four nitrosamines induced a significant number of liver tumours when fed singly, although nitrosophenylbenzylamine induced tumours of the spleen and upper gastrointestinal tract and nitroso-N-methylpiperazine induced tumours of the nasal cavity. Nitrosoproline taken with morpholine did not give rise to tumours, except when given in combination with sodium thiocyanate, which gave rise to an even higher frequency of hepatic tumours when given alone. Nitrosohydroxyproline with morpholine induced liver carcinomas in 3 of 20 rats and in 9 of 20 rats in the presence of sodium thiocyanate. Rats given nitrosophenylbenzylamine plus morpholine lived less than 2 years and 4 of them had liver tumours. Most rats treated with nitrosomethylpiperazine died within a year, because of the tumours induced; the combination with morpholine hydrochloride led to the formation of liver carcinomas in 2 of 20 rats and in 5 of 20 when thiocyanate was given.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7141570

Source DB:  PubMed          Journal:  IARC Sci Publ        ISSN: 0300-5038


  3 in total

Review 1.  Structure-activity relations in carcinogenesis by N-nitroso compounds.

Authors:  W Lijinsky
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

2.  Developing Structure-Activity Relationships for N-Nitrosamine Activity.

Authors:  Kevin P Cross; David J Ponting
Journal:  Comput Toxicol       Date:  2021-09-08

Review 3.  Fifty years of diazeniumdiolate research. From laboratory curiosity to broad-spectrum biomedical advances.

Authors:  Larry K Keefer
Journal:  ACS Chem Biol       Date:  2011-09-30       Impact factor: 5.100

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.